Danaher (DHR) Stock Overview
Designs, manufactures, and markets professional, medical, research, and industrial products and services in the United States, China, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 1/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
DHR Community Fair Values
Create NarrativeSee what 116 others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more
Danaher Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$214.94 |
| 52 Week High | US$242.80 |
| 52 Week Low | US$171.00 |
| Beta | 0.96 |
| 1 Month Change | -8.75% |
| 3 Month Change | -2.83% |
| 1 Year Change | 5.57% |
| 3 Year Change | -15.96% |
| 5 Year Change | -9.46% |
| Change since IPO | 24,139.95% |
Recent News & Updates
Recent updates
Danaher Stock Plunge Does Not Represent A Good Entry Point
Jan 30Some May Be Optimistic About Danaher's (NYSE:DHR) Earnings
Aug 01
Is Danaher Corporation (NYSE:DHR) Trading At A 33% Discount?
Jul 12Is Danaher (NYSE:DHR) A Risky Investment?
May 22Danaher Corporation's (NYSE:DHR) Popularity With Investors Is Clear
May 07Danaher: Some Near-Term Headwinds, But Good Long-Term Prospects And Low Valuations
Mar 31Estimating The Fair Value Of Danaher Corporation (NYSE:DHR)
Mar 26Danaher: Near 5-Year Low Is A Great Entry Point
Mar 22Danaher Corporation Just Missed EPS By 5.5%: Here's What Analysts Think Will Happen Next
Feb 24Danaher: Self-Inflicted Pessimism?
Feb 17Danaher Corporation: Question Mark Behind The Moat And Probably Overvalued
Jan 15Danaher: A Wide-Moat Gem I Cannot Buy Enough Of
Jan 06Danaher: A Resilient And Solid Company With Growth Potential
Dec 10Understanding Danaher's Cautiousness
Oct 25Danaher Q3 Preview: Market Share Gains In Molecular Testing
Sep 25Danaher: Lofty Price, Bright Future
Aug 22Danaher: Valuation Now Too High Even Compared To Own High Standards
Jul 16Mar Vista - Danaher: Headwinds Are Primarily Cyclical, Growth To Regain Momentum
Jun 20Shareholder Returns
| DHR | US Life Sciences | US Market | |
|---|---|---|---|
| 7D | -0.4% | -6.3% | 0.5% |
| 1Y | 5.6% | -5.9% | 10.7% |
Return vs Industry: DHR exceeded the US Life Sciences industry which returned -5.9% over the past year.
Return vs Market: DHR underperformed the US Market which returned 10.7% over the past year.
Price Volatility
| DHR volatility | |
|---|---|
| DHR Average Weekly Movement | 3.3% |
| Life Sciences Industry Average Movement | 7.8% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 16.3% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: DHR has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: DHR's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1969 | 60,000 | Rainer Blair | www.danaher.com |
Danaher Corporation designs, manufactures, and markets professional, medical, research, and industrial products and services in the United States, China, and internationally. It operates through Biotechnology, Life Sciences, and Diagnostics segments. The Biotechnology segment provides bioprocessing technologies, consumables, services, and solutions that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, and aseptic fill finish; single-use hardware, consumables, and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services for diagnostic and assay development; and healthcare filtration solutions.
Danaher Corporation Fundamentals Summary
| DHR fundamental statistics | |
|---|---|
| Market cap | US$155.50b |
| Earnings (TTM) | US$3.60b |
| Revenue (TTM) | US$24.57b |
Is DHR overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| DHR income statement (TTM) | |
|---|---|
| Revenue | US$24.57b |
| Cost of Revenue | US$10.05b |
| Gross Profit | US$14.52b |
| Other Expenses | US$10.92b |
| Earnings | US$3.60b |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | 5.09 |
| Gross Margin | 59.11% |
| Net Profit Margin | 14.65% |
| Debt/Equity Ratio | 35.1% |
How did DHR perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/02/12 22:48 |
| End of Day Share Price | 2026/02/12 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Danaher Corporation is covered by 41 analysts. 23 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| John Eade | Argus Research Company |
| Catherine Ramsey Schulte | Baird |
| Robert Cornell | Barclays |